Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

• Published in: Clinical & translational oncology Vol. 19; no. 12; pp. 1537 - 1542
• Main Authors: Remon, J., Isla, D., Garrido, P., de Castro, J., Majem, M., Viñolas, N., Artal, A., Carcereny, E., García-Campelo, M. R., Lianes, P., Provencio, M., Juan, O., Diz, P., Blanco, R., Lopez-Castro, R., Maestu, I., Vadell, C., Felip, E.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-12-2017
• Subjects: Brief Research Article; Medicine; Medicine & Public Health; Oncology; Women; TKI; Advanced; NSCLC; mutant; EGFR mutant
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-017-1700-8

Background
The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.
Methods
WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (
EGFR
) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.
Results
From October 2007 to December 2012, a total of 1775 NSCLC women were recruited.
EGFR
mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.
Conclusion
Prevalence of
EGFR
mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.